Rhinovirus infections and immunisation induce cross-serotype reactive antibodies to VP1

Antiviral Research

Volumn 95, Issue 3, 2012, Pages 193-201

  McLean, Gary R ^a,d   Walton, Ross P ^a   Shetty, Shweta ^a   Paktiawal, Nasren ^a   Kebadze, Tatiana ^a   Gogsadze, Leila ^a   Niespodziana, Katarzyna ^b   Valenta, Rudolf ^b,c   Bartlett, Nathan W ^a   Johnston, Sebastian L ^a,d  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d LONDON METROPOLITAN UNIVERSITY   (United Kingdom)

Author keywords

Antibodies; Mouse model; Rhinovirus; Vaccine

Indexed keywords

ADJUVANT; CAPSID PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CROSS REACTION; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; LUNG LAVAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHINOVIRUS INFECTION; SERUM; VIRUS ATTACHMENT;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BRONCHOALVEOLAR LAVAGE FLUID; CROSS REACTIONS; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; PICORNAVIRIDAE INFECTIONS; RHINOVIRUS; VIRAL PROTEINS; VIRAL VACCINES;

MIRIDAE; RHINOVIRUS;

EID: 84864055644     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.06.006     Document Type: Article

References (41)

1. Barclay W.S., Al-Nakib W. An ELISA for the detection of rhinovirus specific antibody in serum and nasal secretion. J. Virol. Methods 1987, 15:53-64.
2. Barclay W.S., Callow K.A., Sergeant M., Al-Nakib W. Evaluation of an enzyme-linked immunosorbent assay that measures rhinovirus-specific antibodies in human sera and nasal secretions. J. Med. Virol. 1988, 25:475-482.
3. Barclay W.S., Al-Nakib W., Higgins P.G., Tyrrell D.A. The time course of the humoral immune response to rhinovirus infection. Epidemiol. Infect. 1989, 103:659-669.
4. Barnett P.V., Rowlands D.J., Parry N.R. Characterization of monoclonal antibodies raised against a synthetic peptide capable of inducing a neutralizing response to human rhinovirus type 2. J. Gen. Virol. 1993, 74(Pt 7):1295-1302.
5. Barnett P.V., Rowlands D.J., Campbell R.O., Parry N.R. Monoclonal antibodies to a peptide of human rhinovirus type 2 with different specificities recognize the same minimum sequence. J. Gen. Virol. 1995, 76(Pt 5):1255-1261.
6. Bartlett N.W., Walton R.P., Edwards M.R., Aniscenko J., Caramori G., Zhu J., Glanville N., Choy K.J., Jourdan P., Burnet J., Tuthill T.J., Pedrick M.S., Hurle M.J., Plumpton C., Sharp N.A., Bussell J.N., Swallow D.M., Schwarze J., Guy B., Almond J.W., Jeffery P.K., Lloyd C.M., Papi A., Killington R.A., Rowlands D.J., Blair E.D., Clarke N.J., Johnston S.L. Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nat. Med. 2008, 14:199-204.
7. Carey B.S., Barclay W.S., Russell S.M., Tyrrell D.A. The specificity of antibodies induced by infection with rhinovirus type 2. J. Med. Virol. 1992, 36:251-258.
8. Conant R.M., Hamparian V.V. Rhinoviruses: Basis for a numbering system. 1. HeLa cells for propagationand serologic procedures. J. Immunol. 1968, 100:107-113.
9. Conant R.M., Hamparian V.V. Rhinoviruses: Basis for a numbering system. II. Serologic characterization of prototype strains. J. Immunol. 1968, 100:114-119.
10. Coutelier J.P., van der Logt J.T., Heessen F.W., Warnier G., Van Snick J. IgG2a restriction of murine antibodies elicited by viral infections. J. Exp. Med. 1987, 165:64-69.
11. Douglas R.G., Rossen R.D., Butler W.T., Couch R.B. Rhinovirus neutralizing antibody in tears, parotid saliva, nasal secretions and serum. J. Immunol. 1967, 99:297-303.
12. Edlmayr J., Niespodziana K., Linhart B., Focke-Tejkl M., Westritschnig K., Scheiblhofer S., Stoecklinger A., Kneidinger M., Valent P., Campana R., Thalhamer J., Popow-Kraupp T., Valenta R. A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen Phl p 1. J. Immunol. 2009, 182:6298-6306.
13. Edlmayr J., Niespodziana K., Popow-Kraupp T., Krzyzanek V., Focke-Tejkl M., Blaas D., Grote M., Valenta R. Antibodies induced with recombinant VP1 from human rhinovirus exhibit cross-neutralisation. Eur. Respir. J. 2011, 37:44-52.
14. Fox J.P. Is a rhinovirus vaccine possible?. Am. J. Epidemiol. 1976, 103:345-354.
15. Greenberg S.B. Rhinovirus and coronavirus infections. Semin. Respir. Crit. Care Med. 2007, 28:182-192.
16. Greve J.M., Davis G., Meyer A.M., Forte C.P., Yost S.C., Marlor C.W., Kamarck M.E., McClelland A. The major human rhinovirus receptor is ICAM-1. Cell 1989, 56:839-847.
17. Gwaltney J.M. Virology and immunology of the common cold. Rhinol. 1985, 23:265-271.
18. Hofer F., Gruenberger M., Kowalski H., Machat H., Huettinger M., Kuechler E., Blaas D. Members of the low density lipoprotein receptor family mediate cell entry of a minor-group common cold virus. Proc. Natl. Acad. Sci. USA. 1994, 91:1839-1842.
19. Jackson D.J., Gangnon R.E., Evans M.D., Roberg K.A., Anderson E.L., Pappas T.E., Printz M.C., Lee W.M., Shult P.A., Reisdorf E., Carlson-Dakes K.T., Salazar L.P., DaSilva D.F., Tisler C.J., Gern J.E., Lemanske R.F. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am. J. Respir. Crit. Care Med. 2008, 178:667-672.
20. Johnston S.L., Pattemore P.K., Sanderson G., Smith S., Lampe F., Josephs L., Symington P., O'Toole S., Myint S.H., Tyrrell D.A., et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. Bmj 1995, 310:1225-1229.
21. Johnston S.L., Papi A., Bates P.J., Mastronarde J.G., Monick M.M., Hunninghake G.W. Low grade rhinovirus infection induces a prolonged release of IL-8 in pulmonary epithelium. J. Immunol. 1998, 160:6172-6181.
22. Kainulainen L., Vuorinen T., Rantakokko-Jalava K., Osterback R., Ruuskanen O. Recurrent and persistent respiratory tract viral infections in patients with primary hypogammaglobulinemia. J. Allergy Clin. Immunol. 2010, 126:120-126.
23. Katpally U., Fu T.M., Freed D.C., Casimiro D.R., Smith T.J. Antibodies to the buried N terminus of rhinovirus VP4 exhibit cross-serotypic neutralization. J. Virol. 2009, 83:7040-7048.
24. Knopf H.L., Perkins J.C., Bertran D.M., Kapikian A.Z., Chanock R.M. Analysis of the neutralizing activity in nasal wash and serum following intranasal vaccinaion with inactivated type 13 rhinovirus. J. Immunol. 1970, 104:566-573.
25. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 2002, 20:709-760.
26. Laine P., Blomqvist S., Savolainen C., Andries K., Hovi T. Alignment of capsid protein VP1 sequences of all human rhinovirus prototype strains: conserved motifs and functional domains. J. Gen. Virol. 2006, 87:129-138.
27. Ledford R.M., Patel N.R., Demenczuk T.M., Watanyar A., Herbertz T., Collett M.S., Pevear D.C. VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds. J. Virol. 2004, 78:3663-3674.
28. Lewis J.K., Bothner B., Smith T.J., Siuzdak G. Antiviral agent blocks breathing of the common cold virus. Proc. Natl. Acad. Sci. USA. 1998, 95:6774-6778.
29. Murray C.S., Poletti G., Kebadze T., Morris J., Woodcock A., Johnston S.L., Custovic A. Study of modifiable risk factors for asthma exacerbations: virus infection and allergen exposure increase the risk of asthma hospital admissions in children. Thorax 2006, 61:376-382.
30. Neuberger M.S., Rajewsky K. Activation of mouse complement by monoclonal mouse antibodies. Eur. J. Immunol. 1981, 11:1012-1016.
31. Niespodziana K., Napora K., Cabauatan C., Focke-Tejkl M., Keller W., Niederberger V., Tsolia M., Christodoulou I., Papadopoulos N.G., Valenta R. Misdirected antibody responses against an N-terminal epitope on human rhinovirus VP1 as explanation for recurrent RV infections. Faseb. J. 2011, 25:25.
32. Perkins J.C., Tucker D.N., Knope H.L., Wenzel R.P., Hornick R.B., Kapikian A.Z., Chanock R.M. Evidence for protective effect of an inactivated rhinovirus vaccine administered by the nasal route. Am. J. Epidemiol. 1969, 90:319-326.
33. Renegar K.B., Small P.A., Boykins L.G., Wright P.F. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J. Immunol. 2004, 173:1978-1986.
34. Rhinoviruses: a numbering system., 1967. Nature 213, 761-762.
35. Rossmann M.G., Arnold E., Erickson J.W., Frankenberger E.A., Griffith J.P., Hecht H.J., Johnson J.E., Kamer G., Luo M., Mosser A.G., et al. Structure of a human common cold virus and functional relationship to other picornaviruses. Nature 1985, 317:145-153.
36. Schieble J.H., Fox V.L., Lester F., Lennette E.H. Rhinoviruses: an antigenic study of the prototype virus strains. Proc. Soc. Exp. Biol. Med. 1974, 147:541-545.
37. Sherry B., Mosser A.G., Colonno R.J., Rueckert R.R. Use of monoclonal antibodies to identify four neutralization immunogens on a common cold picornavirus, human rhinovirus 14. J. Virol. 1986, 57:246-257.
38. Skern T., Neubauer C., Frasel L., Grundler P., Sommergruber W., Zorn M., Kuechler E., Blaas D. A neutralizing epitope on human rhinovirus type 2 includes amino acid residues between 153 and 164 of virus capsid protein VP2. J. Gen. Virol. 1987, 68(Pt 2):315-323.
39. Taylor-Robinson D., Johnson K.M., Bloom H.H., Parrott R.H., Mufson M.A., Chanock R.M. Rhinovirus neutralizing antibody responses and their measurement. Am. J. Hyg. 1963, 78:285-292.
40. Turner, R.B., 1997. Epidemiology, pathogenesis, and treatment of the common cold. Ann Allergy Asthma Immunol. 78, 531-539; quiz 539-540.
41. Vlasak M., Blomqvist S., Hovi T., Hewat E., Blaas D. Sequence and structure of human rhinoviruses reveal the basis of receptor discrimination. J. Virol. 2003, 77:6923-6930.